Dexamethasone treatment inhibits VEGF production via suppression of STAT3 in a head and neck cancer cell line

Oncology Reports

Volumn 23, Issue 4, 2010, Pages 1139-1143

  Shim, Seon Hui ^a   Hah, J Hun ^a   Hwang, So Yeon ^a   Heo, Dae Seog ^a,b   Sung, Myung Whun ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Dexamethasone; Head and neck squamous cell carcinoma; Signal transducer and activator of transcription 3; Vascular endothelial growth factor

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; PROTEIN KINASE B; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR RELA; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; DRUG MECHANISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

BLOTTING, WESTERN; CELL LINE, TUMOR; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOCORTICOIDS; HEAD AND NECK NEOPLASMS; HUMANS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77949442228     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000743     Document Type: Article

References (25)

1. Kofler R: The molecular basis of glucocorticoid-induced apoptosis of lymphoblastic leukemia cells. Histochem Cell Biol 114: 1-7, 2000.
2. Planey SL and Litwack G: Glucocorticoid-induced apoptosis in lymphocytes. Biochem Biophys Res Commun 279: 307-312, 2000.
3. Evans-Storms RB and Cidlowski JA: Delineation of an antiapoptotic action of glucocorticoids in hepatoma cells: the role of nuclear factor-kB. Endocrinology 141: 1854-1862, 2000.
4. Sanchez I, Goya L, Vallerga AK and Firestone GL: Glucocorticoids reversibly arrest rat hepatoma-cell growth by inducing an early G(1) block in cell-cycle progression. Cell Growth Differ 4: 215-225, 1993.
5. Wang Z and Garabedian MJ: Modulation of glucocorticoid receptor transcriptional activation, phosphorylation, and growth inhibition by p27(Kip1). J Biol Chem 278: 50897-50901, 2003.
6. Schmidt S, Rainer J, Ploner C, Presul E, Riml S and Kofler R: Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ 11: S45-S55, 2004.
7. Harmon JM, Norman MR, Fowlkes BJ and Thompson EB: Dexamethasone induces irreversible G1 arrest and death of a human lymphoid-cell line. J Cell Physiol 98: 267-278, 1979.
8. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M and Debatin KM: Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63: 3112-3120, 2003.
9. Sommer P, Le Rouzic P, Gillingham H, Berry A, Kayahara M, Huynh T, White A and Ray DW: Glucocorticoid receptor overexpression exerts an antisurvival effect on human small cell lung cancer cells. Oncogene 26: 7111-7121, 2007.
10. Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X and Budunova I: Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26: 1885-1896, 2007.
11. Yano A, Fujii Y, Iwai A, Kageyama Y and Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12: 3003-3009, 2006.
12. Wilson C, Scullin P, Worthington J, Seaton A, Maxwell P, O'Rourke D, Johnston PG, McKeown SR, Wilson RH, O'Sullivan JM and Waugh DJ: Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. Br J Cancer 99: 2054-2064, 2008.
13. Necela BM and Cidlowski JA: Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells. Proc Am Thorac Soc 1: 239-246, 2008.
14. Yu H and Jove R: New molecular targets come of the age. Nat Rev Cancer 4: 97-105, 2004.
15. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R and Yu H: Constitutive STAT3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21: 2000-2008, 2002.
16. Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R and Huang S: Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res 66: 3188-3196, 2006.
17. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R and Yu H: Targeting STAT3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24: 5552-5560, 2005.
18. Jung JE, Lee HG, Cho IH, Chung DH, Yoon SH, Yang YM, Lee JW, Choi S, Park JW, Ye SK and Chung MH: STAT3 is a potential modulator of HIF-1-mediated VEGF expression in human renal carcinoma cells. FASEB J 19: 1296-1298, 2005.
19. Shim SH, Sung MW, Park SW and Heo DS: Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. Int J Mol Med 23: 805-810, 2009.
20. Fidler IJ and Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79: 185-188, 1994.
21. Chen Z and Han ZC: STAT3: a critical transcription activator in angiogenesis. Med Res Rev 28: 185-200, 2008.
22. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
23. Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE and Cidlowski JA: Autoregulation of glucocorticoid receptor gene expression. Steroids 56: 52-58, 1991.
24. Matthews L, Berry A, Tersigni M, D'Acquisto F, Ianaro A and Ray D: Thiazolidinediones are partial agonists for the glucocorticoid receptor. Endocrinology 150: 75-86, 2009.
25. Egberts JH, Schniewind B, Patzold M, Kettler B, Tepel J, Kalthoff H and Trauzold A: Dexamethasone reduces tumor recurrence and metastasis after pancreatic tumor resection in SCID mice. Cancer Biol Ther 7: 1044-1050, 2008.